Quantification by LC-MSE of outer membrane vesicle proteins of the Bexsero® vaccine

Vaccine

Volumn 32, Issue 11, 2014, Pages 1273-1279

  Tani, Chiara ^a   Stella, Maria ^a   Donnarumma, Danilo ^a   Biagini, Massimiliano ^a   Parente, Pierino ^a   Vadi, Alessandro ^a   Magagnoli, Claudia ^a   Costantino, Paolo ^a   Rigat, Fabio ^a   Norais, Nathalie ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Bexsero ; Neisseria meningitidis; Outer membrane vesicles; Quantitative proteomics; Vaccine

Indexed keywords

BEXSERO(®); NEISSERIA MENINGITIDIS; OUTER MEMBRANE VESICLES; QUANTITATIVE PROTEOMICS; VACCINE;

BACTERIAL OUTER MEMBRANE PROTEINS; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; MASS SPECTROMETRY; MENINGOCOCCAL VACCINES; QUALITY CONTROL;

EID: 84893929367     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.011     Document Type: Article

References (49)

1. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl 2):B51-B63.
2. Wyle F.A., Artenstein M.S., Brandt B.L., Tramont E.C., Kasper D.L., Altieri P.L., Berman S.L., Lowenthal J.P. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972, 126(5):514-521.
3. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001, 19(17-19):2688-2691.
4. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., Jennings G.T., Baldi L., Bartolini E., Capecchi B., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
5. Serruto D., Bottomley M.J., Ram S., Giuliani M.M., Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012, 30(Suppl 2):B87-B97.
6. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Froholm L.O., Lindbak A.K., Mogster B., Namork E., Rye U., et al. Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991, 14(2):67-79. discussion 79-80.
7. Bai X., Findlow J., Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011, 11(7):969-985.
8. Gorringe A.R., Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother 2012, 8(2):174-183.
9. Riedmann E.M. MenB candidate vaccine Bexsero induces robust immune response in infants. Hum Vaccin Immunother 2012, 8(3):282.
10. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23(17-18):2191-2196.
11. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen J.H., Halstensen A., Holten E., Lindbak A.K., Nokleby H., Rosenqvist E., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991, 338(8775):1093-1096.
12. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., Martinez M., Arthur J., Underwood P., Silva W., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile, Chilean National Committee for Meningococcal Disease. Vaccine 1995, 13(9):821-829.
13. de Moraes J.C., Perkins B.A., Camargo M.C., Hidalgo N.T., Barbosa H.A., Sacchi C.T., Landgraf I.M., Gattas V.L., Vasconcelos Hde G., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992, 340(8827):1074-1078.
14. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., Casanueva G.V., Rico C.O., Rodriguez C.R., Terry M.H. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14(2):195-207. discussion 208-110.
15. Finney M., Vaughan T., Taylor S., Hudson M.J., Pratt C., Wheeler J.X., Vipond C., Feavers I., Jones C., Findlow J., et al. Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Hum Vaccines 2008, 4(1):23-30.
16. Tsolakos N., Lie K., Bolstad K., Maslen S., Kristiansen P.A., Hoiby E.A., Wallington A., Vipond C., Skehel M., Tang C.M., et al. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media. Vaccine 2010, 28(18):3211-3218.
17. Vipond C., Wheeler J.X., Jones C., Feavers I.M., Suker J. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum Vaccines 2005, 1(2):80-84.
18. Gil J., Betancourt L.Z., Sardinas G., Yero D., Niebla O., Delgado M., Garcia D., Pajon R., Sanchez A., Gonzalez L.J., et al. Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens. Hum Vaccines 2009, 5(5):347-356.
19. Ferrari G., Garaguso I., Adu-Bobie J., Doro F., Taddei A.R., Biolchi A., Brunelli B., Giuliani M.M., Pizza M., Norais N., et al. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 2006, 6(6):1856-1866.
20. Vipond C., Suker J., Jones C., Tang C., Feavers I.M., Wheeler J.X. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 2006, 6(11):3400-3413.
21. Finamore F., Pieroni L., Ronci M., Marzano V., Mortera S.L., Romano M., Cortese C., Federici G., Urbani A. Proteomics investigation of human platelets by shotgun nUPLC-MSE and 2DE experimental strategies: a comparative study. Blood Transfus 2010, 8(Suppl 3):s140-s148.
22. Vissers J.P., Langridge J.I., Aerts J.M. Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 2007, 6(5):755-766.
23. Silva J.C., Denny R., Dorschel C., Gorenstein M.V., Li G.Z., Richardson K., Wall D., Geromanos S.J. Simultaneous qualitative and quantitative analysis of the Escherichia coli proteome: a sweet tale. Mol Cell Proteomics 2006, 5(4):589-607.
24. Silva J.C., Gorenstein M.V., Li G.Z., Vissers J.P., Geromanos S.J. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics 2006, 5(1):144-156.
25. Magagnoli C., Bardotti A., De Conciliis G., Galasso R., Tomei M., Campa C., Pennatini C., Cerchioni M., Fabbri B., Giannini S., et al. Structural organization of NadADelta(351-405), a recombinant MenB vaccine component, by its physico-chemical characterization at drug substance level. Vaccine 2009, 27(15):2156-2170.
26. Martino A., Magagnoli C., De Conciliis G., D'Ascenzi S., Forster M.J., Allen L., Brookes C., Taylor S., Bai X., Findlow J., et al. Structural characterisation, stability and antibody recognition of chimeric NHBA-GNA1030: an investigational vaccine component against Neisseria meningitidis. Vaccine 2012, 30(7):1330-1342.
27. Creskey M.C., Li C., Wang J., Girard M., Lorbetskie B., Gravel C., Farnsworth A., Li X., Smith D.G., Cyr T.D. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Vaccine 2012, 30(32):4762-4770.
28. Getie-Kebtie M., Sultana I., Eichelberger M., Alterman M. Label-free mass spectrometry-based quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines. Influenza Other Respir Viruses 2013, 7(4):521-530.
29. Williams T.L., Pirkle J.L., Barr J.R. Simultaneous quantification of hemagglutinin and neuraminidase of influenza virus using isotope dilution mass spectrometry. Vaccine 2012, 30(14):2475-2482.
30. Yu N.Y., Wagner J.R., Laird M.R., Melli G., Rey S., Lo R., Dao P., Sahinalp S.C., Ester M., Foster L.J., et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics 2010, 26(13):1608-1615.
31. Madan Babu M., Sankaran K. DOLOP-database of bacterial lipoproteins. Bioinformatics 2002, 18(4):641-643.
32. Ruijne N., Lea R.A., O'Hallahan J., Oster P., Martin D. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin Vaccine Immunol 2006, 13(7):797-801.
33. van der Ley P., Heckels J.E., Virji M., Hoogerhout P., Poolman J.T. Topology of outer membrane porins in pathogenic Neisseria spp. Infect Immun 1991, 59(9):2963-2971.
34. Kovacs-Simon A., Titball R.W., Michell S.L. Lipoproteins of bacterial pathogens. Infect Immun 2011, 79(2):548-561.
35. Dallo S.F., Zhang B., Denno J., Hong S., Tsai A., Haskins W., Ye J.Y., Weitao T. Association of Acinetobacter baumannii EF-Tu with cell surface, outer membrane vesicles, and fibronectin. Sci World J 2012, 2012:128705.
36. Doro F., Liberatori S., Rodriguez-Ortega M.J., Rinaudo C.D., Rosini R., Mora M., Scarselli M., Altindis E., D'Aurizio R., Stella M., et al. Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1. Mol Cell Proteomics 2009, 8(7):1728-1737.
37. Rodriguez-Ortega M.J., Norais N., Bensi G., Liberatori S., Capo S., Mora M., Scarselli M., Doro F., Ferrari G., Garaguso I., et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006, 24(2):191-197.
38. van de Waterbeemd B., Mommen G.P., Pennings J.L., Eppink M.H., Wijffels R.H., van der Pol L.A., de Jong A.P. Quantitative proteomics reveals distinct differences in the protein content of outer membrane vesicle vaccines. J Proteome Res 2013, [Epub ahead of print].
39. Centers for Disease Control and Prevention Serogroup Y meningococcal disease-Illinois, Connecticut, and selected areas, United States, 1989-1996. JAMA 1996, 276(23):1866-1867.
40. Wright J.C., Williams J.N., Christodoulides M., Heckels J.E. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun 2002, 70(8):4028-4034.
41. Manning D.S., Reschke D.K., Judd R.C. Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis are similar to Haemophilus influenzae D-15-Ag and Pasteurella multocida Oma87. Microb Pathog 1998, 25(1):11-21.
42. Sardinas G., Yero D., Climent Y., Caballero E., Cobas K., Niebla O. Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential. J Med Microbiol 2009, 58(Pt 2):196-208.
43. Hung M.C., Salim O., Williams J.N., Heckels J.E., Christodoulides M. The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate. Infect Immun 2011, 79(9):3784-3791.
44. Stork M., Bos M.P., Jongerius I., de Kok N., Schilders I., Weynants V.E., Poolman J.T., Tommassen J. An outer membrane receptor of Neisseria meningitidis involved in zinc acquisition with vaccine potential. PLoS Pathog 2010, 6:e1000969.
45. van der Ende A., Hopman C.T., Zaat S., Essink B.B., Berkhout B., Dankert J. Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the -10 and -35 regions of the promoter. J Bacteriol 1995, 177(9):2475-2480.
46. Sarkari J., Pandit N., Moxon E.R., Achtman M. Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly-cytidine. Mol Microbiol 1994, 13(2):207-217.
47. van Ulsen P., Kuhn K., Prinz T., Legner H., Schmid P., Baumann C., Tommassen J. Identification of proteins of Neisseria meningitidis induced under iron-limiting conditions using the isobaric tandem mass tag (TMT) labeling approach. Proteomics 2009, 9(7):1771-1781.
48. Pawlik M.C., Hubert K., Joseph B., Claus H., Schoen C., Vogel U. The zinc-responsive regulon of Neisseria meningitidis comprises 17 genes under control of a Zur element. J Bacteriol 2012, 194(23):6594-6603.
49. Holst J., Feiring B., Naess L.M., Norheim G., Kristiansen P., Hoiby E.A., Bryn K., Oster P., Costantino P., Taha M.K., et al. The concept of tailor-made, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005, 23(17-18):2202-2205.